

SUPPLEMENTARY DATA

**Supplementary Table. Number of patients with type 1 diabetes associated with interferon therapy (IFN-T1D) or type 1A diabetes (T1AD) for whom data on GAD65 antibodies, fasting serum C-peptide, and insulin dosage were available at designated time points.**

	IFN-T1D (n=12)	T1AD (n=128)
GAD65 antibodies		
at onset	12	61
at 1 year	9	17
at 2-4 years	7	55
Fasting C-peptide value		
at onset	12	49
at 1 year	10	36
at 2-4 years	6	102
Insulin dose		
at onset	12	37
at 1 year	11	19
at 2-4 years	8	97

**Supplementary Table 2. Allele frequencies of HLA-A and haplotype frequencies of HLA DR-DQ among the patients with interferon-associated type 1 diabetes (IFN-T1D) and those who did not develop diabetes despite interferon therapy for chronic hepatitis C (DM-negative despite IFN).**

	IFN-T1D (%) (n=24)*	DM-negative despite IFN (%) (n=20)*	OR (95% CI)	p
HLA-A allele				
A*2402	50.0 (12/24)	20.0 (4/20)	4.00 (1.09-17.26)	0.045
A*02	20.8 (5/24)	30.0 (6/20)	0.61 (0.15-2.43)	0.49
A*3303	25.0 (6/24)	15.0 (3/20)	1.89 (0.43-10.9)	0.42
A*1101	4.2 (1/24)	5.0 (1/20)	0.39 (0.017-4.40)	0.46
DR-DQ haplotype				
DRB1*1302-DQA1*0102-DQB1*0604	37.5 (9/24)	35.0 (7/20)	1.11 (0.32-3.93)	0.86
DRB1*0405-DQA1*03-DQB1*0401	12.5 (3/24)	10.0 (2/20)	1.29 (0.19-10.6)	0.80
DRB1*0901-DQA1*03-DQB1*0303	25.0 (6/24)	20.0 (4/20)	1.33 (0.32-6.02)	0.69
DRB1*0803-DQA1*0103-DQB1*0601	4.2 (1/24)	10.0 (2/20)	0.39 (0.02-4.40)	0.46

Alleles or haplotypes of which at least one copy existed in both groups are shown. OR: Odds ratio, CI: confidence interval. \*Numbers of alleles or haplotypes are shown.

SUPPLEMENTARY DATA

**Supplementary Table 3. Genotype of hepatitis C virus (HCV) and details of interferon therapy in patients with interferon-associated type 1 diabetes (IFN-T1D) and those who did not develop diabetes despite interferon therapy (DM-negative despite IFN).**

	IFN-T1D (n=12)	DM-negative despite IFN (n=10)	p
Genotype of HCV (1b/2a/2b)	11/0/1	8/2/0	0.57*
Type of interferon† (α/α2a/α2b/β/PEG-α2a/PEG-α2b)	8/4/2/1/2/3	3/0/1/3/1/4	0.20/0.10/1.00/0.29/1.00/0.65‡
Interferon given in combination with rivabirin (yes/no)	5/7	4/6	1.00
Total number of a course of interferon therapy	1.8 ± 0.9 (1-4)	1.5 ± 0.8 (1-3)	0.31
Total dose of interferon (MU)	803 ± 448 (126-1,634) (n=10)	1,859 ± 1,608 (336-4,296) (n=6)	0.26
Total dose of peginterferon (μg)	4,670 ± 3,346 (880-9,000) (n=5)	4,604 ± 1,853 (2,400-7,500) (n=5)	1.00
Age at completion or disruption of interferon therapy	59.0 ± 8.9	49.8 ± 11.3	0.075

Data are mean ± SD (range). \*Frequency of genotype 1b was compared. †All but one patient with interferon-associated type 1 diabetes and 3 of 10 patients who did not develop diabetes despite interferon therapy were treated with several types of interferon. ‡Frequency of each type of interferon was compared. PEG: Peginterferon.